Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
About the study
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Patient has provided written informed consent
- Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma
- Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma
EXCLUSION CRITERIA
Exclusion Criteria:
- Patient has a prior history of being a subject in an interventional clinical trial for IMLYGIC
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Melanoma,Herpetic Infection
Participants Needed
300
Est. Completion Date
Jan 7, 2038
Treatment Type
OBSERVATIONAL
Sponsor
Amgen
ClinicalTrials.gov NCT Identifier
NCT02910557
Study Number
20130193
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?